- Home
- GNPX vs LDWY Comparison
GNPX vs LDWY Comparison
Compare GNPX & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- LDWY
- Stock Information
- Founded
- GNPX 2009
- LDWY 1990
- Country
- GNPX United States
- LDWY United States
- Employees
- GNPX N/A
- LDWY N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- LDWY Advertising
- Sector
- GNPX Health Care
- LDWY Consumer Discretionary
- Exchange
- GNPX Nasdaq
- LDWY Nasdaq
- Market Cap
- GNPX 6.1M
- LDWY 6.7M
- IPO Year
- GNPX 2018
- LDWY 1991
- Fundamental
- Price
- GNPX $0.38
- LDWY $3.78
- Analyst Decision
- GNPX Strong Buy
- LDWY
- Analyst Count
- GNPX 1
- LDWY 0
- Target Price
- GNPX $10.00
- LDWY N/A
- AVG Volume (30 Days)
- GNPX 6.0M
- LDWY 1.9K
- Earning Date
- GNPX 05-13-2025
- LDWY 03-27-2025
- Dividend Yield
- GNPX N/A
- LDWY N/A
- EPS Growth
- GNPX N/A
- LDWY N/A
- EPS
- GNPX N/A
- LDWY N/A
- Revenue
- GNPX N/A
- LDWY $37,773,000.00
- Revenue This Year
- GNPX N/A
- LDWY N/A
- Revenue Next Year
- GNPX N/A
- LDWY N/A
- P/E Ratio
- GNPX N/A
- LDWY N/A
- Revenue Growth
- GNPX N/A
- LDWY N/A
- 52 Week Low
- GNPX $0.22
- LDWY $3.02
- 52 Week High
- GNPX $4.09
- LDWY $6.88
- Technical
- Relative Strength Index (RSI)
- GNPX 43.09
- LDWY 41.13
- Support Level
- GNPX $0.22
- LDWY $3.71
- Resistance Level
- GNPX $0.39
- LDWY $3.85
- Average True Range (ATR)
- GNPX 0.06
- LDWY 0.07
- MACD
- GNPX 0.00
- LDWY 0.01
- Stochastic Oscillator
- GNPX 31.23
- LDWY 43.59
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.